Use of in Vivo-Induced Antigen Technology for Identification of Escherichia coli O157:H7 Proteins Expressed during Human Infection
Kudva, Indira T.
Griffin, Robert W.
Dodson, Allen W.
Hillman, Jeffrey D.
Tarr, Phillip I.
Calderwood, Stephen B.
MetadataShow full item record
CitationJohn, M., I. T. Kudva, R. W. Griffin, A. W. Dodson, B. McManus, B. Krastins, D. Sarracino, et al. 2005. “Use of In Vivo-Induced Antigen Technology for Identification of Escherichia Coli O157:H7 Proteins Expressed during Human Infection.” Infection and Immunity73 (5): 2665–79. doi:10.1128/IAI.73.5.2665-2679.2005.
AbstractUsing in vivo-induced antigen technology (IVIAT), a modified immunoscreening technique that circumvents the need for animal models, we directly identified immunogenic Escherichia coli O157:H7 (O157) proteins expressed either specifically during human infection but not during growth under standard laboratory conditions or at significantly higher levels in vivo than in vitro. IVIAT identified 223 O157 proteins expressed during human infection, several of which were unique to this study. These in vivo-induced (ivi) proteins, encoded by ivi genes, mapped to the backbone, O islands (OIs), and pO157. Lack of in vitro expression of O157-specific ivi proteins was confirmed by proteomic analysis of a mid-exponential-phase culture of E. coli O157 grown in LB broth. Because ivi proteins are expressed in response to specific cues during infection and might help pathogens adapt to and counter hostile in vivo environments, those identified in this study are potential targets for drug and vaccine development. Also, such proteins may be exploited as markers of O157 infection in stool specimens.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:41542716
- HMS Scholarly Articles